Aggressive control and treatment of risk factors should be considered in order to prevent acute heart failure. Coronary artery disease is managed with aspirin, beta-blockers, statins, and ACE inhibitors.
Optimizing treatment of hypertension, smoking cessation, and lipid control provides substantial benefit in patients with coronary artery disease.
Optimal control of hypertension may require more than one antihypertensive medication.
For the general population, regular physical activity, maintenance of a normal weight, healthy dietary patterns, and avoidance of smoking are also recommended to reduce future risk of heart failure.[2]Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 May 3;145(18):e895-1032.
https://www.ahajournals.org/doi/full/10.1161/CIR.0000000000001063
http://www.ncbi.nlm.nih.gov/pubmed/35363499?tool=bestpractice.com
In asymptomatic patients with reduced left ventricular ejection fraction (LVEF), ACE inhibitors are cardioprotective and reduce further decline in LVEF.[27]Konstam MA, Kronenberg MW, Rousseau MF, et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. SOLVD (Studies of Left Ventricular Dysfunction) Investigators. Circulation. 1993 Nov;88(5 Pt 1):2277-83.
https://www.ahajournals.org/doi/epdf/10.1161/01.CIR.88.5.2277
http://www.ncbi.nlm.nih.gov/pubmed/8222122?tool=bestpractice.com
Beta-blockers may also be considered in this group of patients.
All patients with diabetes mellitus, in addition to metabolic control, need aggressive control of lipids, BP (target <130/80 mmHg) and should be treated with an ACE inhibitor, regardless of the level of the left ventricular (LV) dysfunction, when other cardiovascular risk factors are present.[28]Yusuf S, Sleight P, Pogue J, et al; the Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000 Jan 20;342(3):145-53.
http://www.nejm.org/doi/full/10.1056/NEJM200001203420301#t=article
http://www.ncbi.nlm.nih.gov/pubmed/10639539?tool=bestpractice.com
Patients with type 2 diabetes and either established cardiovascular disease or at high cardiovascular risk should use sodium-glucose cotransporter 2 (SGLT2) inhibitors (e.g., dapagliflozin, empagliflozin, or sotagliflozin) to prevent hospitalizations for heart failure.[2]Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 May 3;145(18):e895-1032.
https://www.ahajournals.org/doi/full/10.1161/CIR.0000000000001063
http://www.ncbi.nlm.nih.gov/pubmed/35363499?tool=bestpractice.com
[29]Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019 Jan 5;393(10166):31-9.
http://www.ncbi.nlm.nih.gov/pubmed/30424892?tool=bestpractice.com
Patients with diabetes taking SGLT2 inhibitors are at increased risk of developing diabetic ketoacidosis (including euglycemic ketoacidosis).[30]Musso G, Saba F, Cassader M, et al. Diabetic ketoacidosis with SGLT2 inhibitors. BMJ. 2020 Nov 12;371:m4147.
http://www.ncbi.nlm.nih.gov/pubmed/33184044?tool=bestpractice.com
Alcohol consumption and excessive salt and fluid intake should be discouraged in patients with known LV dysfunction.[1]McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 Sep 21;42(36):3599-726.
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
http://www.ncbi.nlm.nih.gov/pubmed/34447992?tool=bestpractice.com
[2]Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 May 3;145(18):e895-1032.
https://www.ahajournals.org/doi/full/10.1161/CIR.0000000000001063
http://www.ncbi.nlm.nih.gov/pubmed/35363499?tool=bestpractice.com
Drugs that can cause or potentiate heart failure should be avoided, if possible.[31]Page RL, O'Bryant CL, Cheng D, et al. Drugs that may cause or exacerbate heart failure: a scientific statement from the American Heart Association. Circulation. 2016 Aug 9;134(6):e32-69.
http://circ.ahajournals.org/content/134/6/e32.long
http://www.ncbi.nlm.nih.gov/pubmed/27400984?tool=bestpractice.com